Foralumab

DB16170Investigational

Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 epsilon chain and T-cell surface glycoprotein CD3
Curator reviewed
Code names: NI-0401 · TZLS-401

Resolves to

Compound

UNIIJ43DL56H6MCAS946415-64-1

Targets

P07766CD3E

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

11Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Foralumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account